Hongri Pharmaceutical: Injection of polymyxin E sulfate sodium has obtained clinical trial approval.

Red Sun Pharmaceutical announced that the company recently received a Drug Clinical Trial Approval Notice issued by the National Medical Products Administration. After review, the injection of sodium colistin E sulfonate applied for by the company meets the relevant requirements for drug registration, and the clinical trial of this product has been approved. This drug is suitable for acute or chronic infections caused by Gram-negative bacteria sensitive strains, especially those caused by Pseudomonas aeruginosa sensitive strains.